Haven't used CapNostics yet?
Ask Trustburn

What reviewers say about CapNostics

Based on 9 reviews on Trustburn · updated 88 days ago

Across the reviews, customers consistently describe CapNostics as professional and reliable, frequently praising their attention to detail, prompt support, efficient service, and overall quality, which aligns with the 3.8 out of 5 average rating.
What does CapNostics do?

CapNostics has developed an FDA cleared, non-endoscopic swallowable screening device used to retrieve esophageal cells for early detection of conditions such as Barrett's Esophagus, upper GI cancers, and H-pylori. The company is also positioned to pair this 510k-cleared device with new genome sequencing biomarker diagnostic tests aimed at outpatient screening.

What are the most common complaints about CapNostics?

The 9 reviews on file contain no clear complaints; only 4 of the 9 reviews are below 5 stars, and even those are 3- and 4-star ratings that include positive remarks, so specific recurring complaints are not evident from the available information.

Based on reviews on this page. Verify anything important with the company directly.

Questions & Answers

No questions yet — be the first to ask.

News & Press

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying widget on your website — its a simple way to convert your visitors into customers.

Embed code

<script src="https://trustburn.com/widgets/index.js"></script>
<div class="trustburn-widget" data-trustburn-protocol="https:" data-trustburn-domain="trustburn.com" data-trustburn-widget="score" data-company-path="capnostics-com" data-lang="en"></div>
More widgets

About CapNostics

FDA cleared device for early detection of Barrett’s Esophagus and other Upper GI diseases such as cancer and H-pylori.
Opportunity to launch the FDA 510k clearedNon-endoscopic swallowable screening device for esophageal bottle-brush cellular retrieval for use with new Genome Sequencing diagnostic tests (Biomarkers) that are expected to become mass "out-patient" screening tests used for the early detection of Barrett’s Esophagus and other diseases.